The congenital heart defect devices in USA market is expected to increase by USD 217 million, at a compound annual growth rate (CAGR) of 6.3% from 2022 to 2028, according to the latest edition of the Congenital Heart Defect Devices Market in USA Report.

This industry report offers market estimates of the USA market, followed by a detailed analysis of the product. The USA market data on congenital heart defect devices can be segmented by product: pulmonary and cardiovascular patches, pulmonary valve conduits, septal occluders, mechanical mitral valves. The pulmonary and cardiovascular patches segment held the largest share of the USA congenital heart defect devices market in 2021 and is anticipated to hold its share during the forecast period.

As of 2021, the major players in the USA congenital heart defect devices market were Abbott Laboratories, Edwards Lifesciences Corporation, Medtronic plc, W. L. Gore & Associates Inc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
– Get a detailed picture of the USA Congenital Heart Defect Devices Market
– Identify segments/areas to invest in over the forecast period in the USA Congenital Heart Defect Devices Market
– Understand the competitive environment, the market’s leading players
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.